Proximal Ventures Closes $27.5M Debut Fund for Pharma AI

TL;DR
San Francisco-based Proximal Ventures has closed its debut fund, Fund I, at $27.5 million, beating its original $25 million target, to back pre-seed and seed startups building AI-native software and infrastructure across the pharmaceutical value chain. Founder and Managing Partner Sahir Raoof, a former SignalFire investor who previously worked at Flatiron Health and Iterative Health, is writing checks of $500,000 to $1.5 million into companies spanning computational drug discovery, clinical development, manufacturing, and commercialization. Backers include VC firms SignalFire and Kleiner Perkins, strategic investors Domino Lane, Bertelsmann Healthcare Investments, PagsGroup, Signature Ventures, and Amkan Ventures, plus individual investors including Dimension Capital co-founders Nan Li and Zavain Dar. The firm has already deployed into seven startups, including ChronicleBio, co-founded by former OpenAI executive Fidji Simo.
Key Takeaways
A solo-GP debut fund raised $27.5 million in one of the hardest fundraising environments for new managers in years. First-time fund managers broadly have struggled to raise in 2026 even as established firms keep attracting capital, which makes Proximal's oversubscribed first close notable on timing alone, independent of its specific thesis.
Other venture firms backing a solo GP's debut fund as LPs is an unusual signal. SignalFire and Kleiner Perkins appear on Proximal's own backer list, meaning two multi-stage firms chose to commit LP capital to a first-time, narrowly focused fund rather than relying solely on their own direct deal flow in the sector. That is a stronger vote of confidence in Raoof specifically than a typical angel or family-office check would be.
The thesis is a narrow vertical bet, not a generalist healthcare-AI fund. Proximal invests exclusively in AI-native tools, infrastructure, and services sold into the pharmaceutical industry, explicitly across discovery, development, manufacturing, and commercialization, rather than healthtech broadly or consumer-facing health apps. Raoof's own framing is that pharma has historically been a weak software buyer but a strong buyer of outsourced services, and that AI can convert some of that services spend into venture-scale software businesses.
The portfolio already includes a well-known founder. ChronicleBio, co-founded by Fidji Simo (former CEO of Instacart and, until July 2025, OpenAI's head of applications and later AGI deployment) alongside CEO Rohit Gupta, is one of Proximal's seven disclosed investments. Simo has been public about starting the company after her own diagnosis with POTS, a chronic neuroimmune condition, which gives Proximal an unusually high-profile name in an otherwise early and undisclosed portfolio.
Fund Overview
Fund Name: Proximal Ventures, Fund I
Fund Size: $27.5 million (final close, exceeded $25 million target)
Stage: Pre-seed and seed
Check Size: $500,000 to $1.5 million
Geography: San Francisco-based firm; no stated geographic restriction on portfolio companies
Focus: AI-native software, infrastructure, and services across the pharmaceutical value chain, from computational drug discovery through clinical development, manufacturing, and commercialization
Key LPs: SignalFire, Kleiner Perkins, Domino Lane, Bertelsmann Healthcare Investments, PagsGroup, Signature Ventures, and Amkan Ventures, along with individual investors including Dimension Capital co-founders Nan Li and Zavain Dar
Why This Fund Matters
Most pharma-focused venture capital still concentrates on the drug discovery end of the value chain, where AI-for-biology has attracted the bulk of recent funding and attention. Proximal's stated bet is that the bigger, less-covered opportunity sits downstream: the clinical trial operations, manufacturing logistics, regulatory work, and commercial launch processes that pharmaceutical companies have historically outsourced to specialized service providers rather than buying as software. Raoof has pointed to legal and financial services as sectors where AI has already shown it can displace service-based spending, and is betting pharma services follow a similar path.
The backer list is arguably the more interesting story than the fund size itself. A $27.5 million debut fund is modest by venture standards, but having SignalFire and Kleiner Perkins as LPs, alongside a healthcare-focused strategic investor in Bertelsmann Healthcare Investments, suggests institutional confidence that goes beyond a typical first-time-manager bet. TechCrunch reporting quotes Amy Abernethy, a Proximal investor and former FDA principal deputy commissioner who worked with Raoof at Flatiron Health, crediting his relationship-building and ability to spot industry bottlenecks, and noting that those qualities have already helped Proximal win allocation in competitive rounds alongside much larger funds.
Raoof's own background is the clearest explanation for why a solo-GP fund this specialized could raise successfully right now. He was the first commercial hire and VP of Business Development at Iterative Health, built biopharma research partnerships at Flatiron Health before its $1.9 billion acquisition by Roche in 2018, covered biotech and outsourced pharma services at J.P. Morgan, and spent two years as a principal leading techbio and pharmatech investing at SignalFire. That combination of sales experience and sector-specific investing track record is Proximal's explicit pitch to founders: help with the initial commercial flywheel into pharma, which Raoof has called one of the hardest parts of selling into life sciences, often starting before a company is even incorporated.
What's not yet disclosed is the ownership and governance structure between Raoof and Proximal's institutional LPs, and how the fund's advisory network, which includes Amy Abernethy and GSK Chief AI Officer Kim Branson, is compensated or incentivized relative to a typical venture scout or advisor arrangement. Founders evaluating Proximal should ask directly how hands-on that network actually gets involved in diligence and customer introductions, since that support is central to the firm's pitch.
The Team
Sahir Raoof is Founder and Managing Partner of Proximal Ventures. Before launching the firm in 2026, he spent two years as a principal at SignalFire leading techbio and pharmatech investing, was the first commercial hire and Vice President of Business Development at clinical trial recruitment startup Iterative Health, built biopharma research partnerships at Flatiron Health (the oncology data company Roche acquired for $1.9 billion in 2018), and earlier covered biotech and outsourced pharma services at J.P. Morgan. Proximal's advisory network includes Amy Abernethy, co-founder of Highlander Health and former principal deputy commissioner of the U.S. Food and Drug Administration, who first worked with Raoof at Flatiron Health, and Kim Branson, Chief AI Officer at GSK, among other senior pharma and techbio leaders who work with Proximal's portfolio companies on customer introductions and go-to-market strategy.
Early Portfolio
Proximal has already backed seven startups out of Fund I, though only one has been named publicly so far. ChronicleBio, based in Menlo Park, California, is building an AI-driven data platform to identify biological subtypes within complex chronic neuroimmune conditions like POTS, long COVID, and ME/CFS, with the goal of matching patient subgroups to existing or shelved drug candidates rather than starting development from scratch. The company was co-founded by Rohit Gupta, who serves as CEO and previously oversaw biobanks at Stanford and UCSF, Rishi Reddy, a managing director at Tarsadia Investments, and Fidji Simo, the former Instacart CEO and OpenAI applications and AGI deployment executive, who has spoken publicly about her own POTS diagnosis as a motivation for the company. Proximal's remaining six portfolio companies have not yet been disclosed.
What This Means for Founders
Founders building AI-native software or infrastructure for any part of the pharmaceutical value chain, drug discovery tooling, clinical trial operations, manufacturing and supply chain systems, or commercial and market-access software, are squarely in Proximal's stated mandate, and the firm says it will engage even before a company is incorporated. That's a meaningfully earlier entry point than most seed funds offer, but it comes with a trade-off: Proximal's entire value proposition rests on Raoof's personal pharma relationships and its advisory network's willingness to make introductions, so founders should expect diligence that probes hard on go-to-market feasibility and customer access, not just technical differentiation.
Founders targeting the historically underfunded, service-heavy segments of pharma, manufacturing, regulatory submissions, clinical operations, and commercialization in particular, may find Proximal a more natural fit than generalist AI or healthtech investors who gravitate toward drug discovery. The $500,000 to $1.5 million check range signals a fund comfortable leading or co-leading a company's first institutional round, rather than only participating in rounds already anchored by a larger lead.
Fund Momentum Take
The more durable story here isn't the $27.5 million, it's that a first-time solo GP with a tightly scoped, services-to-software thesis could get SignalFire and Kleiner Perkins to LP into a fund that will inevitably compete with some of their own direct sourcing in techbio and pharmatech. That only happens when LPs are underwriting the person as much as the thesis, and Raoof's decade of pharma-specific operating and investing experience is doing real work here that a generic AI-in-healthcare pitch wouldn't. The open test is whether a $500,000 to $1.5 million check, backed mostly by relationship capital rather than deep reserves, is enough to compete for allocation as these companies raise larger rounds from multi-stage firms that can write much bigger checks later.
Frequently Asked Questions
What is Proximal Ventures?
A San Francisco-based, independent early-stage venture capital firm founded by Sahir Raoof in 2026, investing in AI-native software and infrastructure across the pharmaceutical value chain, from drug discovery through clinical development, manufacturing, and commercialization.
How much did Proximal Ventures raise?
$27.5 million for its debut fund, Fund I, exceeding its original $25 million target.
What size checks does Proximal write?
$500,000 to $1.5 million into pre-seed and seed-stage companies.
Who are Proximal's investors?
SignalFire, Kleiner Perkins, Domino Lane, Bertelsmann Healthcare Investments, PagsGroup, Signature Ventures, and Amkan Ventures, plus individual investors including Dimension Capital co-founders Nan Li and Zavain Dar.
What companies has Proximal backed?
Seven startups to date, though only ChronicleBio, co-founded by former OpenAI executive Fidji Simo, has been publicly named. The remaining six have not been disclosed.
Raising a fund? Submit your fund to be featured on Fund Momentum.
Need help with your fundraise? Explore fundraising advisory services.
Related funds in the index
Pre Seed · AI/ML funds from the verified index
| Fund | Size | Stage | Location | Focus |
|---|---|---|---|---|
| Plural Fund III | €1 billion combined, with roughly two-thirds allocated to new early-stage investments EUR | Pre Seed | United Kingdom | Defense, EnergyTech +3 |
| Northside Ventures Fund II | $30 million USD target USD | Pre Seed | Canada | AI/ML, Robotics & Automation +1 |
| Mission Street Capital, Fund 0 | $2M USD | Pre Seed | United States | AI/ML |
| Zacua Ventures Fund II | $135M USD | Pre Seed | United States | Built Environment, Manufacturing +3 |
| Enza Capital AI Africa Fund III | $21M USD | Pre Seed | Kenya | AI/ML |